Register for our free email digests:
Latest From Fortress Biotech Inc.
Emerging Company Profile: The two-year-old company combines the Fortress Biotech model with City of Hope's broad expertise in CAR-T technology, plus leadership from a pioneer in the space.
Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.
Public biopharma offerings gained momentum, including four IPOs during the last week of June, as US investors looked kindly on the sector ahead of July 4 celebrations. Also, VC investment continued unabated as Atlas Venture closed a new $350m fund.
Scrip analyses the potential of "hot" immunotherapy mechanisms, such as PD-1 inhibitors and CAR-T therapies, in various stages of clinical development for glioblastoma.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- 4SC AG
- Senior Management
Jason Loveridge, PhD, CEO
Frank Hermann, MD, Chief Dev. Officer
Roland Baumgartner, PhD, CSO
Susanne Danhauser-Riedl, MD, CMO
- Contact Info
Phone: (49) 89 700763 0
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.